## ABT: Abbott Laboratories - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.7% below STRENGTH zone (3.0-6.0%); PEG 4.17 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($120.29)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Is Weakness In Abbott Laboratories (NYSE:ABT) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?**
- Source: Yahoo Finance Singapore | 20251227T140734 | Somewhat-Bullish | Relevance: 100%
- Despite a recent 6.5% decline in Abbott Laboratories' stock, the article suggests its strong financials, particularly an impressive 27% Return on Equity (ROE), might indicate the market is underestimating its potential. The company's ROE significantly surpasses the industry average of 9.8%, and it has maintained a modest 18% net income growth over five years. However, future analyst estimates predict a decline in ROE and earnings, despite a projected decrease in its payout ratio.

**2. Rede Wealth LLC Purchases New Stake in Abbott Laboratories $ABT**
- Source: MarketBeat | 20251228T120456 | Somewhat-Bullish | Relevance: 100%
- Rede Wealth LLC initiated a new position in Abbott Laboratories (ABT) during the third quarter, acquiring 8,208 shares valued at approximately $1.10 million. This investment represents about 0.9% of Rede Wealth's portfolio. Abbott Laboratories recently reported Q3 EPS of $1.30, met analyst estimates, and raised its quarterly dividend to $0.63 per share, yielding 2.0% annually.

**3. Abbott Laboratories $ABT Shares Sold by Pacer Advisors Inc.**
- Source: MarketBeat | 20251228T110745 | Somewhat-Bullish | Relevance: 100%
- Pacer Advisors Inc. reduced its stake in Abbott Laboratories (NYSE:ABT) by 6.7% in Q3, selling 10,297 shares and now holding 143,188 shares valued at approximately $19.18 million. The company reported EPS of $1.30 and revenue of $11.37 billion for Q3, while also increasing its quarterly dividend to $0.63, reflecting a 2.0% yield. Analysts have issued an average price target of $147.00 for ABT, with a "Moderate Buy" rating.

**4. U.S. Embolic Protection Devices Market and Competition Analysis, 2025-2033, Featuring Abbott Laboratories, Allium Medical Solutions, Boston Scientific, Cardinal Health and More**
- Source: Yahoo Finance | 20251229T162823 | Somewhat-Bullish | Relevance: 94%
- The U.S. Embolic Protection Device Market is projected to grow from US$360 million in 2024 to US$650 million by 2033, with a CAGR of 6.96%. This growth is primarily driven by the increasing prevalence of cardiovascular diseases, an aging population, and technological advancements in device design. Key challenges include the high cost of devices and complexities in reimbursement, as well as the need for highly skilled operators to properly use these devices.

**5. Recombinant Therapeutic Antibodies And Proteins Market**
- Source: openPR.com | 20251229T053856 | Somewhat-Bullish | Relevance: 73%
- The Recombinant Therapeutic Antibodies And Proteins Market is projected for substantial growth from 2025 to 2032 due to rising demand, expanding applications, and technological advancements. Coherent Market Insights' report provides a comprehensive overview of market size, revenue trends, key growth factors, and competitive landscape. The study offers actionable insights for businesses to make informed decisions in this high-growth sector.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.39M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.2%)
- Blackrock Inc.: 8.1% (+0.2%)
- State Street Corpora: 4.5% (-0.2%)
- Capital Internationa: 3.5% (+2.5%)
- JPMORGAN CHASE & CO: 3.4% (+49.5%)

### Key Risks

1. Valuation stretched: PEG 4.2x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 4.17 signals overvaluation risk, limited margin of safety. Forward P/E 22.0x stretched relative to 10% growth. Quality metrics strong (ROE 31%, margin 32%). Balance sheet: $2.3B free cash flow. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $216.8B |
| Beta | 0.71 |
| 52W Range | $110.86 - $141.23 |
| Short Interest | 0.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.17 |
| Forward P/E | 22.0 |
| Current P/E | 24.1 |
| YoY Growth | 9.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -0.6% to -1.7% (-1.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.7pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.1%) - potential reversal signal. Below SMA200 (0.96x), long-term trend not supportive. RSI neutral at 46. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.66% (CS: 20) | Neutral |
| RSI_14 | 45.5 | Neutral |
| MACD Histogram | 0.04 | Bullish |
| vs SMA20 | 0.996x | Below |
| vs SMA50 | 0.987x | Below |
| vs SMA200 | 0.958x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $124.61
- **Stop Loss:** $120.29 (3.5% risk)
- **Target:** $128.93 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 319
- **Position Value:** $39,750.59
- **Portfolio %:** 39.75%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite and defensive rotation. VIX at 14.2 (2nd percentile) signals low volatility, while positive yield curve (+58bps) and stable economic indicators support continued expansion. Market breadth at 58.7% shows decent participation, but rotation into defensive names and Fed liquidity concerns warrant measured positioning.*

### Earnings

**Next:** 2026-01-21 (Est: $1.50)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.30 | $1.30 | +0.1% |
| 2025Q2 | $1.26 | $1.26 | +0.3% |
| 2025Q1 | $1.07 | $1.09 | +1.7% |
| 2024Q4 | $1.34 | $1.34 | -0.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*